 Julie Harral
Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 17 | 2023 | 1946 | 0.710 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 6 | 2011 | 51 | 0.370 |
Why?
| | Anemia, Sickle Cell | 3 | 2020 | 312 | 0.330 |
Why?
| | Lung | 14 | 2023 | 4084 | 0.330 |
Why?
| | Heart Ventricles | 7 | 2023 | 750 | 0.310 |
Why?
| | Pulmonary Artery | 10 | 2022 | 1124 | 0.300 |
Why?
| | Hypoxia | 8 | 2023 | 1193 | 0.280 |
Why?
| | Hemoglobins | 2 | 2019 | 381 | 0.240 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2012 | 440 | 0.220 |
Why?
| | Microvessels | 3 | 2018 | 98 | 0.220 |
Why?
| | Exercise Tolerance | 2 | 2025 | 282 | 0.220 |
Why?
| | Glucosephosphate Dehydrogenase Deficiency | 1 | 2025 | 34 | 0.210 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2025 | 70 | 0.210 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 241 | 0.190 |
Why?
| | Animals | 29 | 2025 | 37800 | 0.170 |
Why?
| | Scleroderma, Systemic | 1 | 2022 | 123 | 0.170 |
Why?
| | Vascular Remodeling | 2 | 2022 | 203 | 0.170 |
Why?
| | Mice | 21 | 2025 | 18218 | 0.170 |
Why?
| | Cigarette Smoking | 1 | 2022 | 99 | 0.160 |
Why?
| | Endothelial Cells | 5 | 2023 | 862 | 0.160 |
Why?
| | Beta vulgaris | 1 | 2020 | 14 | 0.160 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2023 | 248 | 0.160 |
Why?
| | Emulsions | 1 | 2019 | 57 | 0.150 |
Why?
| | Disease Models, Animal | 8 | 2025 | 4525 | 0.150 |
Why?
| | Pulmonary Emphysema | 1 | 2022 | 275 | 0.150 |
Why?
| | Pulmonary Edema | 1 | 2019 | 105 | 0.150 |
Why?
| | Mice, Transgenic | 8 | 2025 | 2177 | 0.150 |
Why?
| | Respiratory Tract Infections | 1 | 2023 | 394 | 0.140 |
Why?
| | Evans Blue | 1 | 2018 | 8 | 0.140 |
Why?
| | Polycystic Kidney Diseases | 1 | 2019 | 71 | 0.140 |
Why?
| | Blood Vessels | 3 | 2016 | 167 | 0.140 |
Why?
| | Fluorocarbons | 1 | 2019 | 119 | 0.140 |
Why?
| | Capillary Permeability | 1 | 2018 | 132 | 0.130 |
Why?
| | Physical Exertion | 1 | 2018 | 205 | 0.130 |
Why?
| | Rats | 8 | 2022 | 5553 | 0.130 |
Why?
| | Fibrosis | 1 | 2019 | 547 | 0.120 |
Why?
| | Down Syndrome | 1 | 2023 | 522 | 0.120 |
Why?
| | Water | 1 | 2019 | 465 | 0.120 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 379 | 0.120 |
Why?
| | Neprilysin | 1 | 2016 | 47 | 0.120 |
Why?
| | Ventricular Remodeling | 2 | 2023 | 275 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 6 | 2019 | 2512 | 0.110 |
Why?
| | Myocytes, Smooth Muscle | 3 | 2007 | 263 | 0.110 |
Why?
| | Muscle Contraction | 1 | 2018 | 429 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 919 | 0.110 |
Why?
| | Endotoxins | 1 | 2015 | 217 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 566 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2018 | 2485 | 0.100 |
Why?
| | Altitude | 1 | 2018 | 473 | 0.100 |
Why?
| | Calcium Channels, T-Type | 2 | 2005 | 104 | 0.100 |
Why?
| | Apoptosis | 4 | 2018 | 2395 | 0.100 |
Why?
| | Macrophages | 2 | 2019 | 1496 | 0.100 |
Why?
| | Oxygen | 1 | 2018 | 978 | 0.090 |
Why?
| | Muscle, Skeletal | 2 | 2025 | 1784 | 0.090 |
Why?
| | Vitamin D | 1 | 2015 | 400 | 0.090 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 948 | 0.090 |
Why?
| | Ventricular Function, Right | 4 | 2023 | 296 | 0.080 |
Why?
| | Cytoskeleton | 1 | 2011 | 195 | 0.080 |
Why?
| | Histone Deacetylases | 1 | 2012 | 207 | 0.080 |
Why?
| | Hemolysis | 2 | 2025 | 242 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2012 | 218 | 0.080 |
Why?
| | Transgenes | 2 | 2008 | 190 | 0.080 |
Why?
| | Heart Failure | 1 | 2023 | 2323 | 0.070 |
Why?
| | Blood Pressure | 6 | 2018 | 1763 | 0.070 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2023 | 149 | 0.070 |
Why?
| | Mice, Inbred C57BL | 6 | 2022 | 5954 | 0.070 |
Why?
| | Gene Expression Regulation | 4 | 2016 | 2589 | 0.070 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 62 | 0.070 |
Why?
| | Mutant Proteins | 1 | 2008 | 104 | 0.070 |
Why?
| | Mice, Inbred Strains | 1 | 2008 | 396 | 0.070 |
Why?
| | Muscle, Smooth | 1 | 2008 | 153 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 146 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 4 | 2011 | 749 | 0.060 |
Why?
| | Proteomics | 2 | 2025 | 1182 | 0.060 |
Why?
| | Galectin 1 | 1 | 2006 | 2 | 0.060 |
Why?
| | Pulmonary Circulation | 3 | 2019 | 429 | 0.060 |
Why?
| | Cells, Cultured | 6 | 2012 | 4102 | 0.060 |
Why?
| | Hyperoxia | 1 | 2007 | 96 | 0.060 |
Why?
| | Transforming Growth Factor beta2 | 1 | 2006 | 26 | 0.060 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2006 | 93 | 0.060 |
Why?
| | Multigene Family | 1 | 2006 | 206 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2006 | 191 | 0.050 |
Why?
| | Leukocyte Common Antigens | 3 | 2008 | 87 | 0.050 |
Why?
| | Male | 12 | 2023 | 72263 | 0.050 |
Why?
| | Femur | 1 | 2006 | 250 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 971 | 0.050 |
Why?
| | Pneumonia | 1 | 2009 | 627 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 475 | 0.050 |
Why?
| | Stem Cells | 1 | 2007 | 621 | 0.050 |
Why?
| | Biology | 1 | 2023 | 89 | 0.050 |
Why?
| | Erythrocytes | 2 | 2025 | 750 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2022 | 106 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2008 | 2348 | 0.040 |
Why?
| | CDC2-CDC28 Kinases | 1 | 2001 | 16 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 495 | 0.040 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 120 | 0.040 |
Why?
| | Doxycycline | 2 | 2016 | 62 | 0.040 |
Why?
| | Female | 10 | 2023 | 78137 | 0.040 |
Why?
| | Familial Primary Pulmonary Hypertension | 2 | 2011 | 196 | 0.040 |
Why?
| | Nitric Oxide Synthase | 1 | 2001 | 234 | 0.040 |
Why?
| | Leukocytes | 1 | 2022 | 291 | 0.040 |
Why?
| | Cell Division | 3 | 2009 | 752 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 971 | 0.040 |
Why?
| | Vascular Resistance | 2 | 2015 | 367 | 0.040 |
Why?
| | Humans | 14 | 2025 | 144298 | 0.040 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 294 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 4068 | 0.040 |
Why?
| | Nitrates | 1 | 2020 | 100 | 0.040 |
Why?
| | Phenylpropionates | 1 | 2019 | 27 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1206 | 0.040 |
Why?
| | Pyridazines | 1 | 2019 | 57 | 0.040 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2019 | 34 | 0.040 |
Why?
| | Animals, Newborn | 2 | 2015 | 888 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2001 | 318 | 0.040 |
Why?
| | Gadolinium | 1 | 2019 | 84 | 0.040 |
Why?
| | Metabolomics | 1 | 2025 | 722 | 0.040 |
Why?
| | Fatty Acids | 1 | 2022 | 447 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 193 | 0.040 |
Why?
| | Blotting, Western | 3 | 2009 | 1160 | 0.040 |
Why?
| | AC133 Antigen | 2 | 2008 | 20 | 0.040 |
Why?
| | Tamoxifen | 1 | 2019 | 191 | 0.040 |
Why?
| | Kidney Tubules, Proximal | 1 | 2019 | 130 | 0.040 |
Why?
| | Up-Regulation | 1 | 2001 | 847 | 0.030 |
Why?
| | Endothelins | 1 | 2018 | 61 | 0.030 |
Why?
| | Myofibroblasts | 1 | 2019 | 142 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2025 | 1331 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2001 | 627 | 0.030 |
Why?
| | Signal Transduction | 2 | 2011 | 5182 | 0.030 |
Why?
| | Cell Lineage | 1 | 2019 | 376 | 0.030 |
Why?
| | Nitric Oxide | 2 | 2018 | 894 | 0.030 |
Why?
| | Pyrroles | 1 | 2018 | 210 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2020 | 715 | 0.030 |
Why?
| | Enzyme Activation | 2 | 2011 | 762 | 0.030 |
Why?
| | Acclimatization | 1 | 2018 | 172 | 0.030 |
Why?
| | Glycoproteins | 2 | 2008 | 353 | 0.030 |
Why?
| | Substance P | 1 | 2016 | 38 | 0.030 |
Why?
| | Microcirculation | 2 | 2007 | 141 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2020 | 575 | 0.030 |
Why?
| | Duodenum | 1 | 2016 | 77 | 0.030 |
Why?
| | Phosphorylation | 2 | 2011 | 1702 | 0.030 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2015 | 35 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 512 | 0.030 |
Why?
| | Elastin | 1 | 2015 | 78 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2020 | 2032 | 0.030 |
Why?
| | Antigens, CD | 2 | 2008 | 552 | 0.030 |
Why?
| | Hematocrit | 2 | 2008 | 107 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2007 | 1041 | 0.030 |
Why?
| | Indoles | 1 | 2018 | 500 | 0.030 |
Why?
| | Phenotype | 3 | 2011 | 3139 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2007 | 629 | 0.020 |
Why?
| | Promoter Regions, Genetic | 2 | 2011 | 1244 | 0.020 |
Why?
| | Transfection | 2 | 2007 | 922 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2011 | 1762 | 0.020 |
Why?
| | Genotype | 2 | 2011 | 1843 | 0.020 |
Why?
| | Peptides | 2 | 2008 | 985 | 0.020 |
Why?
| | rac GTP-Binding Proteins | 1 | 2011 | 35 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2011 | 56 | 0.020 |
Why?
| | Receptor, TIE-2 | 1 | 2011 | 11 | 0.020 |
Why?
| | rac1 GTP-Binding Protein | 1 | 2011 | 56 | 0.020 |
Why?
| | Neuropeptides | 1 | 2011 | 74 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2844 | 0.020 |
Why?
| | Ventricular Pressure | 1 | 2011 | 52 | 0.020 |
Why?
| | Chronic Disease | 2 | 2008 | 1809 | 0.020 |
Why?
| | Gene Expression | 2 | 2009 | 1474 | 0.020 |
Why?
| | Benzamides | 1 | 2012 | 224 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2011 | 303 | 0.020 |
Why?
| | Mice, Knockout | 2 | 2009 | 3106 | 0.020 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2011 | 142 | 0.020 |
Why?
| | Regional Blood Flow | 1 | 2012 | 513 | 0.020 |
Why?
| | Flow Cytometry | 2 | 2004 | 1152 | 0.020 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2009 | 55 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 48 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 21 | 0.020 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2009 | 77 | 0.020 |
Why?
| | Smad Proteins | 1 | 2008 | 43 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2011 | 1360 | 0.020 |
Why?
| | Systole | 1 | 2008 | 177 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 518 | 0.020 |
Why?
| | Endothelium | 1 | 2008 | 119 | 0.020 |
Why?
| | Vasoconstriction | 1 | 2009 | 216 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2008 | 171 | 0.020 |
Why?
| | Pyridines | 1 | 2012 | 601 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 264 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 86 | 0.020 |
Why?
| | Thrombosis | 1 | 2011 | 395 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2006 | 3520 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2008 | 2808 | 0.020 |
Why?
| | Species Specificity | 1 | 2008 | 572 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 283 | 0.020 |
Why?
| | Microfilament Proteins | 1 | 2007 | 136 | 0.010 |
Why?
| | Rats, Nude | 1 | 2006 | 25 | 0.010 |
Why?
| | DNA Primers | 1 | 2006 | 507 | 0.010 |
Why?
| | Mibefradil | 1 | 2005 | 9 | 0.010 |
Why?
| | Cell Cycle | 1 | 2008 | 595 | 0.010 |
Why?
| | Diltiazem | 1 | 2005 | 17 | 0.010 |
Why?
| | Muscle Proteins | 1 | 2007 | 240 | 0.010 |
Why?
| | Edema | 1 | 2006 | 123 | 0.010 |
Why?
| | Antigens, Polyomavirus Transforming | 1 | 2004 | 15 | 0.010 |
Why?
| | Cycloheximide | 1 | 2004 | 42 | 0.010 |
Why?
| | Time Factors | 2 | 2007 | 7128 | 0.010 |
Why?
| | Capillaries | 1 | 2006 | 118 | 0.010 |
Why?
| | Electrocardiography | 1 | 2008 | 663 | 0.010 |
Why?
| | Caspase 8 | 1 | 2004 | 47 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2004 | 39 | 0.010 |
Why?
| | Patch-Clamp Techniques | 1 | 2005 | 289 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 54 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 11713 | 0.010 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2004 | 48 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2004 | 100 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2004 | 185 | 0.010 |
Why?
| | Caspases | 1 | 2004 | 228 | 0.010 |
Why?
| | Sheep | 1 | 2006 | 880 | 0.010 |
Why?
| | Actins | 1 | 2006 | 421 | 0.010 |
Why?
| | Organ Specificity | 1 | 2004 | 311 | 0.010 |
Why?
| | Genomics | 1 | 2008 | 828 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2171 | 0.010 |
Why?
| | Pregnancy | 1 | 2015 | 7112 | 0.010 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2004 | 337 | 0.010 |
Why?
| | Telomerase | 1 | 2004 | 249 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 410 | 0.010 |
Why?
| | Extracellular Matrix | 1 | 2006 | 552 | 0.010 |
Why?
| | Tritium | 1 | 2001 | 68 | 0.010 |
Why?
| | Thymidine | 1 | 2001 | 60 | 0.010 |
Why?
| | Cyclin E | 1 | 2001 | 23 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2001 | 64 | 0.010 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 2001 | 35 | 0.010 |
Why?
| | Mutagenesis | 1 | 2001 | 192 | 0.010 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2001 | 122 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2012 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1981 | 0.010 |
Why?
| | Inflammation | 1 | 2011 | 2862 | 0.010 |
Why?
| | Blood Proteins | 1 | 2001 | 233 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2007 | 2033 | 0.010 |
Why?
| | Mitochondria | 1 | 2004 | 981 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2001 | 1699 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1483 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2007 | 6387 | 0.010 |
Why?
| | Biomarkers | 1 | 2007 | 4248 | 0.010 |
Why?
| | DNA | 1 | 2001 | 1444 | 0.010 |
Why?
| | Hypertension | 1 | 2001 | 1259 | 0.010 |
Why?
| | Child | 1 | 2008 | 22562 | 0.000 |
Why?
| | Middle Aged | 1 | 2008 | 35892 | 0.000 |
Why?
| | Adult | 1 | 2008 | 40408 | 0.000 |
Why?
|
|
Harral's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|